TUDORZA PRESSAIR: A long-acting anticholinergic treatment

For the long-term maintenance treatment of bronchospasm in patients with COPD

TUDORZA provides statistically significant improvements in bronchodilation that are consistent over time 1

  • Statistically significant improvements in morning predose lung function (forced expiratory volume in one second [FEV1]) at 12 or 24 weeks vs placebo1-3
  • Improvements in lung function were maintained for 12 hours after the first dose and were consistent over 12 or 24 weeks1
  • No overall differences in efficacy or safety were observed between older (≥70 years) and younger (<70 years) adult patients in 3 placebo-controlled studies1
  • Common side effects occurred at rates of <7%1
    • The most common side effects (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA vs placebo, respectively1
    • The incidence of common anticholinergic side effects was <1%, including dry mouth (0.8% vs 0.6%), constipation (0.0% vs 0.9%), tachycardia (0.3% vs 0.0%), and urinary retention (0.2% vs 0.0%), for TUDORZA vs placebo, respectively2
  • Preloaded, multiple-dose inhaler with dose indicator and colored control window that confirms correct inhalation1
    • For a complete description of how to use the TUDORZA PRESSAIR inhaler, see the step-by-step Instructions for Use within the full Prescribing Information.

To review TUDORZA PRESSAIR clinical data, visit Efficacy   

INDICATIONS AND USAGE

TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

IMPORTANT SAFETY INFORMATION

  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).
  • Inhaled medicines, including TUDORZA, may cause paradoxical bronchospasm. In addition, immediate hypersensitivity reactions may occur after administration of TUDORZA. If either of these occurs, treatment with TUDORZA should be stopped and other treatments considered.
  • TUDORZA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop.
  • Patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to TUDORZA. Use with caution in patients with severe hypersensitivity to milk proteins.
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA vs placebo, respectively.

Please also see the full Prescribing Information.